Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001 Jul; 68(2):171-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.